1. Anderson M (2020) Top 10 pharma companies by revenue. Becker’s Hospital Review. https://www.beckershospitalreview.com/pharmacy/top-10-pharma-companies-by-revenue.html. Accessed 15 Jan 2021
2. Daemmrich A, Bowden ME (2005) A rising drug industry. Chem Eng News 83:28–42
3. Döhner H, Symeonidis A, Sanz MA et al (2016) Phase III randomized trial of volasertib plus low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated AML, ineligible for intensive therapy. Haematologica 101:abstract S501
4. GlaxoSmithKline (2005) Annual report
5. GlaxoSmithKline (2017) Annual report